{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:37:26Z","timestamp":1777246646315,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is the most common and aggressive primary CNS tumor in adults and carries a poor prognosis. Although molecular classification has advanced, patient outcomes remain variable. Next-generation sequencing (NGS) can reveal genomic alterations that, while not yet treatment-guiding, offer prognostic and biological insight. The study aimed to investigate the association between molecular alterations in primary GBM tumors and patient survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed medical records of consecutive GBM patients treated between November 1, 2018 and December 31, 2021 at a comprehensive cancer center, for whom NGS data from the tumor was available. Survival analyses were performed according to clinical, radiological, therapeutic, and molecular data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 199 patients, 38 were excluded: 15 for recurrence-only data and 23 for incomplete molecular data after first progression. In the survival analysis of the cohort (n\u2009=\u2009161) adjusted on surgical resection, MGMT promoter methylation status, number of alterations, age, tumor localization, MIB1 and performance status, EGFR substitutions were significantly associated with increased overall survival (OS) (HR\u2009=\u20090.43 [0.26; 0.72], P\u2009=\u2009.001), while CDKN2A\/B loss and TP53 substitutions were associated with decreased OS (HR\u2009=\u20091.75 [1.08; 2.84], P\u2009=\u2009.023 and HR\u2009=\u20091.69 [1.04; 2.74], P\u2009=\u2009.034 respectively). NOTCH1 substitutions showed a trend towards improved progression-free survival (PFS) (HR\u2009=\u20090.55 [0.30; 1.01], P\u2009=\u2009.054).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified new prognostic markers in GBM, showing for the first time that EGFR substitutions improve OS. Validation in external cohorts and preclinical studies is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag095","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:14:59Z","timestamp":1773404099000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3110-3717","authenticated-orcid":false,"given":"Ad\u00e8le","family":"Meola","sequence":"first","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]},{"name":"INSERM U1037, Cancer Research Center of Toulouse (CRCT) , Toulouse, 31024,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3492-3780","authenticated-orcid":false,"given":"Bertille","family":"Segier","sequence":"additional","affiliation":[{"name":"Biostatistics and Health Data Science Unit, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-4616","authenticated-orcid":false,"given":"Aurore","family":"Siegfried","sequence":"additional","affiliation":[{"name":"INSERM U1037, Cancer Research Center of Toulouse (CRCT) , Toulouse, 31024,","place":["France"]},{"name":"Department of Pathology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Lusque","sequence":"additional","affiliation":[{"name":"Biostatistics and Health Data Science Unit, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne","family":"Evrard","sequence":"additional","affiliation":[{"name":"INSERM U1037, Cancer Research Center of Toulouse (CRCT) , Toulouse, 31024,","place":["France"]},{"name":"Department of Pathology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Dghayem","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Hopital Pierre Paul Riquet, CHU Purpan , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-7117","authenticated-orcid":false,"given":"Franck-Emmanuel","family":"Roux","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hopital Pierre Paul Riquet, CHU Purpan , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00eflys","family":"Guillaumey","sequence":"additional","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilfad","family":"Blazevic","sequence":"additional","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-9276","authenticated-orcid":false,"given":"Elizabeth Cohen-Jonathan","family":"Moyal","sequence":"additional","affiliation":[{"name":"INSERM U1037, Cancer Research Center of Toulouse (CRCT) , Toulouse, 31024,","place":["France"]},{"name":"Department of Radiotherapy, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-7774","authenticated-orcid":false,"given":"Delphine","family":"Larrieu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse, 31059,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026042618472881800_oyag095-B1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026042618472881800_oyag095-B2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \u2018Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u2019","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026042618472881800_oyag095-B3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol"},{"key":"2026042618472881800_oyag095-B4","doi-asserted-by":"publisher","first-page":"vdaa126","DOI":"10.1093\/noajnl\/vdaa126","article-title":"Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026042618472881800_oyag095-B5","doi-asserted-by":"crossref","first-page":"e13107","DOI":"10.1111\/bpa.13107","article-title":"Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas","volume":"32","author":"Liu","year":"2022","journal-title":"Brain Pathol. Zurich Switz"},{"key":"2026042618472881800_oyag095-B6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026042618472881800_oyag095-B7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"key":"2026042618472881800_oyag095-B8","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-23-0926","article-title":"Prognostic markers of DNA methylation and next-generation sequencing in progressive glioblastoma from the EORTC-26101 trial","volume":"29","author":"Kessler","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026042618472881800_oyag095-B9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/annonc\/mdz221","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"30","author":"Long","year":"2019","journal-title":"Ann Oncol"},{"key":"2026042618472881800_oyag095-B10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw."},{"key":"2026042618472881800_oyag095-B11","doi-asserted-by":"publisher","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","article-title":"Molecular targeted therapy of glioblastoma","volume":"80","author":"Le Rhun","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"2026042618472881800_oyag095-B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026042618472881800_oyag095-B13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial","volume":"37","author":"Wen","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026042618472881800_oyag095-B14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J Neurooncol"},{"key":"2026042618472881800_oyag095-B16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/neuonc\/nox151","article-title":"Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro-Oncol"},{"key":"2026042618472881800_oyag095-B17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol"},{"key":"2026042618472881800_oyag095-B18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-Course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042618472881800_oyag095-B19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"2026042618472881800_oyag095-B20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/neuonc\/noab058","article-title":"Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma","volume":"23","author":"Wang","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026042618472881800_oyag095-B22","doi-asserted-by":"publisher","first-page":"vdab008","DOI":"10.1093\/noajnl\/vdab008","article-title":"Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?","volume":"3","author":"Skaga","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026042618472881800_oyag095-B23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/neuonc\/noab282","article-title":"Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making","volume":"24","author":"Lim-Fat","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"key":"2026042618472881800_oyag095-B25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/cncr.11120","article-title":"Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas","volume":"97","author":"Tortosa","year":"2003","journal-title":"Cancer."},{"key":"2026042618472881800_oyag095-B26","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00520-020-05663-y","article-title":"Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias","volume":"29","author":"Frappaz","year":"2021","journal-title":"Support Care Cancer."},{"key":"2026042618472881800_oyag095-B27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11060-009-9946-9","article-title":"Neurological outcome of long-term glioblastoma survivors","volume":"95","author":"Hottinger","year":"2009","journal-title":"J Neurooncol"},{"key":"2026042618472881800_oyag095-B28","doi-asserted-by":"publisher","first-page":"112913","DOI":"10.1016\/j.ejca.2023.05.002","article-title":"Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders\u2019 Collaborative Consortium (EORTC 1419)","volume":"189","author":"Hertler","year":"2023","journal-title":"Eur J Cancer."},{"key":"2026042618472881800_oyag095-B29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.19.00367","article-title":"Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study","volume":"38","author":"Draaisma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026042618472881800_oyag095-B31","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1200\/JCO.2022.40.16_suppl.3139","article-title":"Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): a large mono-institutional experience","volume":"40","author":"Padovan","year":"2022","journal-title":"JCO"},{"key":"2026042618472881800_oyag095-B32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature."},{"key":"2026042618472881800_oyag095-B33","doi-asserted-by":"publisher","first-page":"621432","DOI":"10.3389\/fonc.2021.621432","article-title":"Glioblastoma primary cells retain the most copy number alterations that predict poor survival in glioma patients","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"2026042618472881800_oyag095-B34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz124","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12672-022-00590-2","article-title":"Impact of CDKN2A\/B, MTAP, and TERT genetic alterations on survival in IDH wild type glioblastomas","volume":"13","author":"Hsu","year":"2022","journal-title":"Discov Oncol"},{"key":"2026042618472881800_oyag095-B36","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene."},{"key":"2026042618472881800_oyag095-B37","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"key":"2026042618472881800_oyag095-B39","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026042618472881800_oyag095-B40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"2026042618472881800_oyag095-B41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41392-023-01637-8","article-title":"From signalling pathways to targeted therapies: unravelling glioblastoma\u2019s secrets and harnessing two decades of progress","volume":"8","author":"Dewdney","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026042618472881800_oyag095-B42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/neuonc\/not093","article-title":"Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110","volume":"15","author":"Schulte","year":"2013","journal-title":"Neuro Oncol"},{"key":"2026042618472881800_oyag095-B43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40263-017-0456-6","article-title":"EGFR as a target for glioblastoma treatment: an unfulfilled promise","volume":"31","author":"Westphal","year":"2017","journal-title":"CNS Drugs."},{"key":"2026042618472881800_oyag095-B44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ccell.2018.06.006","article-title":"Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development","volume":"34","author":"Binder","year":"2018","journal-title":"Cancer Cell."},{"key":"2026042618472881800_oyag095-B45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41586-021-04393-3","article-title":"Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias","volume":"602","author":"Hu","year":"2022","journal-title":"Nature."},{"key":"2026042618472881800_oyag095-B46","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/00005072-199807000-00005","article-title":"PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas","volume":"57","author":"Tohma","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026042618472881800_oyag095-B47","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/brain\/awm204","article-title":"Long-term survival with glioblastoma multiforme","volume":"130","author":"Krex","year":"2007","journal-title":"Brain"},{"key":"2026042618472881800_oyag095-B48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1200\/PO.19.00385","article-title":"Landscape of genomic alterations in IDH wild-type glioblastoma identifies PI3K as a favorable prognostic factor","volume":"4","author":"Yan","year":"2020","journal-title":"JCO Precis. Oncol"},{"key":"2026042618472881800_oyag095-B49","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","article-title":"Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide","volume":"21","author":"Wang","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2026042618472881800_oyag095-B50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12935-023-03006-5","article-title":"Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments","volume":"23","author":"Lin","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2026042618472881800_oyag095-B51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-023-02912-y","article-title":"Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma","volume":"23","author":"Chang","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2026042618472881800_oyag095-B52","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag095\/67370331\/oyag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag095\/68103173\/oyag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag095\/68103173\/oyag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:32Z","timestamp":1777243652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag095\/8524928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag095","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,16]]},"article-number":"oyag095"}}